Knesset committee: too much Botox poses health risk

While the US has legal limits on the amount of the toxin that can be used, Israel does not.

November 15, 2017 16:28
1 minute read.
A woman receiving a Botox injection

A woman receiving a Botox injection. (photo credit: ING IMAGE/ASAP)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The botulinum toxin – commonly known as Botox and used to minimize facial wrinkles and achieve other aesthetic preferences – is used too freely by doctors and cosmeticians and poses a health risk, emeritus microbiology Prof. Bracha Rager of Ben-Gurion University of the Negev said at a meeting of the Knesset’s Science and Technology Committee on Tuesday.

Rager, who is outgoing chairman of the Council for Regulation of Research in Biological Diseases, told the committee that US law prohibits the use of certain amounts of botulinum toxin, but that there is no limit on its use in Israel. Neurological diseases such as tics and hyperhidrosis that require only a small amount of the toxin should be exempted from limitations, she said, but under current law, “we cannot stop the use” of larger amounts.

“The problem is the quantities,” Rager said. “If there is no obligation to report on small quantities, we won’t be able to know who ordered the quantities. As far as I am concerned, the safety officer in the institution is responsible for the quantity after reporting to us.”

Dr. Leah Walinsky, director of the molecular biology unit in the Health Ministry, added: “We need to examine whether there are institutional committees that are more stringent and more flexible. As for Botox, I personally would not inject this toxin myself.”

On a separate topic, committee chairman MK Uri Maklev called on the council to demand proper protection in research institutions working with dangerous substances: “This is one of the most sensitive issues today, certainly when we talk about pathogens that could harm many people.” The committee was meeting to discuss the council’s report on its activities in 2015 and 2016.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

May 23, 2019
Regenerative medicine firm CollPlant launches Israel R&D center